Avadel Pharmaceuticals (AVDL) said Tuesday that the US Court of Appeals for the Federal Circuit has vacated the portion of an injunction imposed by a Delaware court that prohibited the company from applying for FDA approval of Lumryz for any indication beyond narcolepsy.
The court also lifted the portions of the Delaware court's injunction that prohibited the company from offering open-label extensions to trial participants using Lumryz and from initiating new clinical trials or studies for potential indications beyond narcolepsy, the company said.
The company said it expects to complete patient enrollment for its REVITALYZ trial, a phase 3 study to evaluate the efficacy and safety of Lumryz, by the end of 2025.
Avadel shares were 3.2% lower in recent trading.
Price: 8.73, Change: -0.31, Percent Change: -3.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.